Axogen priced an upsized underwritten public offering of 4 million shares of common stock at $31.00 per share, with an option for underwriters to purchase an additional 600,000 shares at the same price. The offering is expected to close on January 23, 2026, and will raise approximately $124 million before underwriting discounts and commissions.
The proceeds will be used to repay a $25 million term loan from Oberland Capital, which carries a 9.00% plus LIBOR interest rate. Repayment is expected to reduce annual interest expense by about $2.25 million, strengthening the company’s balance sheet and improving net income.
The financing follows Axogen’s strong preliminary fourth‑quarter and full‑year 2025 revenue results, which projected $59.9 million and $225.2 million respectively—up 21.3% and 20.2% from the same periods in 2024. The upsizing from an initial $85 million target reflects robust investor demand and the company’s intent to support continued growth and product commercialization.
Management emphasized that the capital raise will also fund working capital and capital expenditures, supporting the rollout of its Avance Nerve Graft and Axoguard Nerve Connector products. The FDA approval of the Avance Nerve Graft on December 3, 2025, has expanded the company’s market reach and underpins the confidence in future revenue streams.
The offering price of $31.00 per share is below the market price of $33.01 at the time of pricing, creating immediate dilution for existing shareholders. However, the strategic debt repayment and the ability to invest in high‑margin product lines are expected to offset dilution pressures over the long term.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.